Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients-Reference-Cited by-同舟云学术

Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients

Published:2012-09 Issue:9 Volume:18 Page:1391-1400
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Pergam Steven A.,Xie Hu,Sandhu Ravinder,Pollack Margaret,Smith Jeremy,Stevens-Ayers Terry,Ilieva Valeria,Kimball Louise E.,Huang Meei-Li,Hayes Tracy S.,Corey Lawrence,Boeckh Michael J.

Funder

NIH

Joel Meyers Endowment and an IDSA/Astellas Postdoctoral Fellowship Award in Transplant Infectious Diseases

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference52 articles.

1. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy;Boeckh;Blood,2004

2. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection;Nichols;J Infect Dis,2002

3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy;George;Transpl Infect Dis,2010

4. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources;Walker;Biol Blood Marrow Transplant,2007

5. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality;Matthes-Martin;Bone Marrow Transplant,2003

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors and incidence of cytomegalovirus viremia and disease in pediatric patients with allogeneic hematopoietic stem cell transplantation: An 8‐year single‐center experience in Latin America;Pediatric Transplantation;2022-06

2. American Society for Transplantation and Cellular Therapy Series: #3—Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2021-09

3. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre‐transplant predictors of survival, reactivation, and spontaneous clearance;Transplant Infectious Disease;2021-01-05

4. Recent Approaches and Strategies in the Generation of Anti-human Cytomegalovirus Vaccines;Methods in Molecular Biology;2021

5. Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation;Biology of Blood and Marrow Transplantation;2020-11